#USA #gene therapy #Cell Therapy #College Station #Matica Biotechnology

Matica Biotechnology's Rise in Cell & Gene Therapy Manufacturing

In 2025, Matica Biotechnology, Inc., a prominent Contract Development and Manufacturing Organization (CDMO) based in the U.S., has firmly established itself as the go-to entity for cell and gene therapy (CGT). The company's remarkable growth is underscored by the acquisition of over 10 new manufacturing projects within the first half of the year, surpassing its total revenue from 2024 by the end of Q2.

This surge in activity reflects the increasing demand for CGT solutions from a variety of biotech companies, including foundations, emerging startups, and publicly traded organizations. A notable achievement for Matica includes securing a commercial manufacturing agreement with a mid-sized U.S. biotech firm for the late-stage production of a viral vector therapy. This milestone highlights Matica's expertise in managing complex and regulatory-heavy programs at scale.

Paul Kim, CEO of Matica Biotechnology, remarked, "This year's momentum reflects the trust our clients place in our facility, team, and technology." The company also recently clinched two additional significant Good Manufacturing Practice (GMP) projects, reaffirming its proven capabilities and approach in the sector. Matica prides itself on delivering customized, compliant, and scalable manufacturing solutions both in the U.S. and internationally, through partnerships with institutions like Cha Group Hospitals and Medical University in the Asia Pacific region.

Central to Matica's success is its purpose-built CGT manufacturing facility located in College Station, Texas. This advanced site is exclusively designed for viral vector production and is equipped with a fully single-use system that promotes high productivity, seamless scale-up capabilities, and a reduced risk of contamination. Matica's proprietary MatiMAX™ cell line platform, tailored for AAV (Adeno-Associated Virus) and LVV (Lentiviral Vector) production, combines with state-of-the-art in-house capabilities to guarantee consistent product quality and adherence to regulatory standards.

What sets Matica apart in a competitive marketplace is its adaptable, client-centric approach. Each project is meticulously tailored to meet the unique scientific, technical, and regulatory requirements of its partners, which is a crucial advantage in today's fast-paced and highly scrutinized CGT industry. Min Park, Chief Commercial Officer (CCO) of Matica Biotechnology, stated, "We're not a one-size-fits-all CDMO. Our team collaborates closely with each partner to devise customized solutions that ensure their programs remain on track."

As the sector continues to evolve, Matica is diligently preparing for further expansions in capacity, capabilities, and strategic partnerships to address the growing need for advanced cell and gene therapies.

About Matica Biotechnology, Inc.

Matica Biotechnology stands out as a trusted partner in the viral vector CDMO landscape, leveraging cutting-edge technologies at its cGMP facility. Equipped with leading expertise in process and assay development, as well as GMP manufacturing, Matica provides seamless support to clients through all project stages. In collaboration with various Matica sites worldwide, the organization exemplifies excellence in the CDMO space with innovative solutions, including MatiMax™ proprietary cell lines, continuous process monitoring, and single-use technologies.

For additional information about Matica Biotechnology, please visit www.maticabio.com.